BREAKING

Thursday, January 28, 2021

CytoDyn Inc.’s Vyrologix (leronlimab-Vyrologix) shows impressive results in critically ill COVID-19 patients



Wazzup Pilipinas!

CytoDyn Inc., a late-stage biotechnology company developing CCR5 inhibiting drug leronlimab- Vyrologix, showed impressive results in improving the immune function of critically ill COVID-19 patients in the United States.

Leronlimab- Vyrologix is a humanized monoclonal antibody drug used to treat HIV patients. The drug is a C-C chemokine receptor type 5 (CCR5) antagonist that protects healthy T cells from viral infection. The CCR5 receptor plays a crucial role in modulating immune cell trafficking to sites of inflammation.[1] Because of the drug’s ability to mitigate the cytokine storm which is common in COVID-19 fatalities,[2] it has become the basis for its study as a potential COVID-19 treatment.[3]

Leronlimab- Vyrologix appears to be a powerful treatment with hardly any drug related serious adverse events. CytoDyn’s recent treatment of patients under eIND (Emergency Investigational New Drug) with leronlimab for COVID-19 infection have shown impressive results as the drug reduced the plasma viral load and restored the immune function by day 7.5, [4]

CytoDyn has already completed its Phase 2 clinical trial for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate COVID-19 patients in the U.S. The company has also recently announced that they have completed the enrollment of 394 patients in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population.

Cytodyn has appointed Chiral Pharma, a subsidiary of New Marketlink Pharmaceutical Corporation (NMPC) as its authorized partner for the distribution of Leronlimab-Vyrologix to the Philippines subject to registration approval of Philippine Food and Drug Administration. Through the partnership, the companies are working to register Leronlimab under a licensed physician’s request for Compassionate Special Permit (CSP). It is the desire of Cytodyn and Chiral Pharma to make Leronlimab immediately available to patients with Covid-19.


[1] https://ghr.nlm.nih.gov/gene/CCR5


[2] https://www.webmd.com/lung/news/20200417/cytokine-storms-may-be-fueling-some-covid-deaths


[3] https://www.cytodyn.com/newsroom/press-releases/detail/399/leronlimab-used-in-seven-patients-with-severe-covid-19


[4] https://www.cytodyn.com/newsroom/press-releases/detail/452/impressive-results-from-cytodyns-phase-2-covid-19-trial





About ""

WazzupPilipinas.com is the fastest growing and most awarded blog and social media community that has transcended beyond online media. It has successfully collaborated with all forms of media namely print, radio and television making it the most diverse multimedia organization. The numerous collaborations with hundreds of brands and organizations as online media partner and brand ambassador makes WazzupPilipinas.com a truly successful advocate of everything about the Philippines, and even more since its support extends further to even international organizations including startups and SMEs that have made our country their second home.

Post a Comment

Note: Only a member of this blog may post a comment.

Need professional help with your papers? - Visit this writing service supported by the best academic writers.
 
Copyright © 2013 Wazzup Pilipinas News and Events
Design by FBTemplates | BTT